A download link will be emailed after check out.
Stivarga (regorafenib) is indicated for the treatment of patients with metastatic bowel cancer who were previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy.
